Routine

Obesity

Endocrine · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A chronic disease of excess adiposity driving metabolic and cardiovascular risk. South Asians have higher risk at lower BMI. Management spans lifestyle, pharmacotherapy and bariatric surgery.

Red flags

  • Refer to specialist weight-management (tier 3) for complex obesity, consideration of pharmacotherapy or surgery, and suspected secondary endocrine cause
  • Rarely admitted for obesity itself; admit for acute complications or bariatric surgical issues

Assessment

Investigations

  • BMI and waist circumference, BP
  • Screen metabolic risk: HbA1c/fasting glucose, fasting lipids, LFTs (NAFLD), TSH
  • Consider sleep study if OSA suspected (Epworth, snoring, apnoeas)
  • Exclude secondary endocrine causes only if clinically indicated (Cushingoid features, PCOS)

Management

  • Multicomponent lifestyle: dietary change (500-600 kcal/day deficit), increased activity, behavioural support, structured weight-management programme
  • Pharmacotherapy as adjunct: GLP-1 receptor agonists (semaglutide 2.4mg weekly, liraglutide 3mg) or dual GIP/GLP-1 (tirzepatide), orlistat
  • Bariatric/metabolic surgery for BMI >=40, or >=35 with comorbidity (lower Asian thresholds), via specialist tier-3/4 services
  • Treat comorbidities concurrently

Disposition

Refer to specialist weight-management (tier 3) for complex obesity, consideration of pharmacotherapy or surgery, and suspected secondary endocrine cause.

Complications & pitfalls

  • Type 2 diabetes, cardiovascular disease, OSA, NAFLD/cirrhosis, osteoarthritis, venous thromboembolism, multiple cancers, infertility, psychological morbidity
  • Post-bariatric: nutritional deficiencies, dumping, gallstones

Exam pearls

  • Treat obesity as a chronic relapsing disease, not a willpower failure: weight regain on stopping GLP-1 agents is expected because the drug treats the underlying biology. Use lower BMI and waist thresholds for South Asian patients, who develop metabolic disease at lower weights.
  • Monitoring & follow-up: Track weight, BMI, waist, BP and metabolic markers. Set realistic goals (5-10% loss yields meaningful benefit). Review pharmacotherapy efficacy and tolerability (stop if <5% loss at target dose). Lifelong micronutrient monitoring and supplementation after bariatric surgery.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.